CA2908232C — Nasal administration of fluticasone and carbon dioxide

USPTO Abstract

ABRIDGED: A therapeutic agent is described, comprising fluticasone for the therapeutic treatment of nasal polyps or chronic rhinosinusitis. This therapeutic agent is to be administered in quantities of 100 pg to 400 pg twice daily by means of a delivery device comprising a mouthpiece and a nasal tip, the mouthpiece being placed in the patient's mouth and the nasal tip in the first nostril. In use, exhalation into the mouthpiece creates a flow from the nasal tip into the first nostril, for the purpose of delivering a therapeutic amount of carbon dioxide at a first site in the patient's first nasal passage. The carbon dioxide serves to reduce the pH of the nasal mucosa at the first site in the patient's nasal passage, and the fluticasone is to be administered before or concurrently with the carbon dioxide.